Retension Pharmaceuticals Prices $45M Upsized Nasdaq IPO
Retension Pharmaceuticals, Inc. (NASDAQ: RTSN) priced its upsized initial public offering at $45 million on October 14, 2026. The clinical-stage biopharma company focuses on neurodegenerative diseases. The offering was led by specialized healthcare investment banks and marks its Nasdaq listing.
51CFO view：For biotech firms targeting US IPOs, the CFO must lead GAAP-compliant R&D expense treatment, clinical asset valuation disclosures, and stock-based compensation modeling — all under SEC scrutiny. RTSN’s S-1 filing sets a benchmark for how pre-revenue companies substantiate financial statements and MD&A assumptions.
Retension Pharmaceuticals, Inc. (NASDAQ: RTSN) priced its upsized initial public offering at $45 million on October 14, 2026. The clinical-stage biopharma company focuses on neurodegenerative diseases. The offering was led by specialized healthcare investment banks and marks its Nasdaq listing.
Source：Google News · 美股 IPO
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →